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DENSITY IN PATIENTS WITH PROSTATE CANCER UNDERGOING
ANDROGEN DEPRIVATION THERAPY: SYSTEMATIC REVIEW AND
META-ANALYSIS
H. Bessar 1,*, A. Negida 1, Y. Hani 1, A. Menshawy 3, E. Ghanem2, A. Adel 2, N.
Atallah 2, H. Ahmed 2. 1 Zagazig University, Egypt; 2Al Azhar University,
Egypt; 3Al Menouﬁa University, Egypt
Aim: This study aims at synthesizing evidence from published RCTs about
safety and efﬁcacy of Zoledronic acid (ZA) on bone mineral density (BMD)
for prostate cancer (PCa) patients undergoing androgen deprivation ther-
apy (ADT).
Methods: We searched PubMed through September 2014 using relevant
key words "zoledronic acid", "prostate cancer", and "bone". Data were
extracted from eligible studies, quality was assessed in strict accordance to
Cochrane handbook and data were analyzed using RevMan 5.3 for
windows.
Results: Eight RCTs with a total of 713 patients were eligible for this
study. The pooled mean difference of percentage change in BMD between
ZA and control group favored the ZA group than the control group in
terms of: lumbar spine (MD¼7.80%, 95% CI¼[5.80, 9.80]), total hip
(MD¼3.76%, 95% CI¼[3.18:4.35]) and femoral neck (MD¼3.75%, 95% CI¼
[2:84:4.65]). Of the six adverse events we analyzed (arthralgia, con-
stipation, fatigue, fever, respiratory infection and hot ﬂashes), fever and
fatigue were more common in Zoledronic acid group than control group
(RR¼1.49, 95% CI¼[1.04, 2.12] and RR¼4.27, 95% CI¼[1.59,11.44])
respectively.
Conclusion: Intravenous ZA was safe and tolerated in this population. ZA
achieved therapeutic success (>3% change in BMD) in patients with PCa
undergoing ADT with less adverse events.
0912: ANTIMICROBIAL RESISTENCE IN URINARY TRACT ISOLATES
ASSOCIATED WITH URETERIC STENTS
A. McPhee 1,*, L. Cottom 2, B. Jones 2. 1Gartnavel General Hospital, UK;
2Glasgow Royal Inﬁrmary, UK
Aim: 1. To investigate the microorganisms responsible for UTI in patients
with indwelling J ureteral stents. 2. Compare the frequency distribution of
urinary isolates against Health Protection Scotland data for UTI. 3.
Compare the antimicrobial susceptibility pattern of the isolates against
Health Protection Scotland Data.
Methods: We analysed 6 months theatre records to identify any patients
with an insertion, removal or change or ureteral stent. We then examined
our electronic clinical record system (Clinical Portal) and microbiology
electronic record system (TelePath) for positive urinary cultures. Identi-
fying all positive urine cultures taken while a stent was in situ and
assessing their antimicrobial proﬁles. Finally we assessed the frequency of
individual urinary isolates and compared this to epidemiological data from
the Health Protection Scotland (HPS).
Results: A Statistically Signiﬁcant difference in the distribution of urinary
isolates was noted in our study, X2¼414.951 (p<0.0001), was demon-
strated when compared to HPS epidemiological data.
Our study population demonstrated greater resistance to comparable an-
tibiotics. A statistically signiﬁcant increase in E.Coli resistance towards
Ciproﬂoxacin (p¼0.01), Co-amoxiclav (p¼0.05), Gentamicin (p<0.01) &
Trimethoprim (p<0.01) was demonstrated
Conclusion: Our study shows that urinary isolates associatedwith ureteral
stents were more resistant to antibiotics used as empirical therapy and
peri-operative prophylaxis.
0928: DOES INKING PROSTATE BIOPSIES HELP PREDICT OUTCOMES IN
PROSTATE CANCER?
G. Whittaker 1,*, S. Pomplun 2, A. Chandra 1,2, G. Marra 2, C. Brown2, G.
Muir 2, P. Dasgupta 1,2, H. Yamamoto 1,2. 1King's College London, UK;
2Guy's and St Thomas' NHS Foundation Trust, UK
Aim: To investigate whether capsule-to-cancer distance (CCD) in trans-
rectal ultrasound-guided prostate biopsy (TRUS Bx) samples was useful inpredicting clinical and pathological outcomes in patients undergoing
radical prostatectomy (RP) for prostate cancer (PCa).
Methods: We collected clinical and pathological data for patients who
underwent TRUS Bx and subsequent RP at King’s College Hospital between
April 2011 and October 2013. Distance from the inked capsular end to
cancer in TRUS Bx samples weremeasured by consultant histopathologists.
Tumour on whole-mount RP specimens were also marked, scanned, and
measured for proximity of tumour to the posterior capsule. All statistical
analyses were conducted using Microsoft Excel and GraphPad Prism 5.0.
Results: Out of 310 patients who had inked TRUS Bxs, 46 patients subse-
quently underwent RP. 21.7% had a minimum CCD (MCCD) of 0mm as
assessed by TRUS Bx. TRUS-MCCDwas signiﬁcantly less in patients with an
RP-MCCD of 0mm (p¼0.047). TRUS-MCCD >2mm was associated with
MCCD >0mm in RP specimens (p¼0.03). MCCD did not predict patholog-
ical stage, Gleason score, biochemical recurrence, or margin status.
Conclusion: TRUS-MCCD did not predict ﬁnal pathological stage or onco-
logical outcome after RP. TRUS-MCCD predicted RP-MCCD which could aid
surgical planning. Further research with a larger cohort is necessary.
0937: DOES ENHANCEMENT OF RENAL TUMOUR ON COMPUTED
TOMOGRAPHY IMAGING CORRELATE TO HISTOLOGICAL TYPE OR
GRADE OF TUMOUR?
K. Randhawa, A. Downey*, M. O'Neill, A. Macleod, C.
Mulholland. Altnagelvin Hospital, UK
Aim: Prognosis for renal cell carcinoma depends on stage, grade and his-
tology of tumour. There is increasing evidence that degree of enhancement
betweenpre andpost contrastCT images canassist indetermininggradeand
histology of renal tumours. We investigated whether enhancement on CT
correlated to particular histological types or grades of tumour in our centre.
Methods: Data was collected from 93 patients with renal tumours using
from December 2012 to March 2014. 34 were ineligible (29 no histology, 1
colonic met, 4 benign). Contrast enhancement was deﬁned as >20HU and
measured using local imaging programme.
Results: Of 59 eligible patients, 16 underwent CT with both pre and post
contrast phase. 14 had enhancing lesions; 6 were grade II (mean
enhancement 25.3HU to 74HU), 7 were grade III (31.8HU to 74.14) and 1
was grade IV (42HU - 134). 1 patient wasn't graded on the pathology
report. Therewas no difference between the degree of enhancement in the
different histological subtypes.
Conclusion: Our study showed there was no signiﬁcant difference in
contrast enhancement between grade and histological subtype of RCC.
Further evaluation with a larger patient group could help determine any
correlation between tumour characteristics and degree of contrast
enhancement.
0943: THE DIAGNOSTIC VALUE OF MRI-BASED PSA DENSITY TO
PREDICT THE OUTCOME OF PRIMARY TRANSPERINEAL SECTOR-
GUIDED PROSTATE BIOPSY
F. MacAskill 1,*, D. Eldred-Evans 2, R. Popert 2, T. Carr 1, M. Van
Hemelrijck 2, K. Wolfe 1, S. Liyanage 1. 1 Southend University Hospital, UK;
2Guy's and St Thomas' NHS Foundation Trust, UK
Aim: This study aimed at determining the diagnostic value of MRI-based
PSA density (MR-PSAD) for the presence of prostate cancer on subsequent
transperineal sector-guided prostate biopsies (TPSBx).
Methods: Consecutive biopsy-naive men undergoing primary TPSBx be-
tween 2007 and 2014 were considered. A systematic biopsy protocol was
used. Using MRI, an ellipsoid approximation was used to calculate volume.
Histological outcomes were assessed for the presence of any cancer or sig-
niﬁcant cancer, deﬁnedas either thepresenceofGleason4or4mmtumour
core length (G4) or Gleason 4 or 6mm tumour core length (G6). Receiver
operated characteristics were created and areas under the curve (AUC)with
95% conﬁdence intervals (CI) were compared for PSA and MR-PSAD.
Results: A total of 659 men were evaluated with mean (±SD) age 63 (±9)
years, PSA 8.2 (±5.6) mcg/l, prostate volume 48 (±27) cc and MR-PSAD 0.2
(±0.18) mcg/l/cc. The AUC (95% CI) was signiﬁcantly better for MR-PSAD
than PSA for all cancer deﬁnitions (p0.001): 0.73 (0.69-0.77) vs. 0.61
(0.56-0.65) for any cancer; 0.75 (0.71-0.79) vs. 0.66 (0.61-0.70) for G4; 0.77
